Adverum Biotechnologies, Inc. is shifting its focus to wet age-related macular degeneration (AMD) after discontinuing development of its gene therapy, ADVM-022, in diabetic macular edema (DME) following a series of adverse events among patients with DME who received the therapy. Nevertheless, it faces a tough road ahead as the adverse events could invite scrutiny from physicians, patients and regulators despite not occurring in wet AMD, a disease area that is also highly competitive.
Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
Gene Therapy Company Calls Off Diabetic Macular Edema Program
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.